Session » Systemic Sclerosis and Related Disorders – Basic Science Poster II

Date: Monday, October 22, 2018

Time: 9:00AM-11:00AM

Meeting: 2018 ACR/ARHP Annual Meeting

9:00AM-11:00AM: Abstract Number: 1105

Abatacept Is Effective in Experimental Digestive and Lung Tissue Fibrosis

9:00AM-11:00AM: Abstract Number: 1108

Antibody Repertoire Dynamics in Systemic Sclerosis after Myeloablative Autologous Hematopoietic Stem-Cell Transplantation or Cyclophosphamide Treatment

9:00AM-11:00AM: Abstract Number: 1111

CBS004, a Novel Monoclonal Antibody Against Bdca-2 Inhibits TLR-Induced Activation of Human pDC in Vitro and In Vivo. a Novel Therapeutic Target for Systemic Sclerosis

9:00AM-11:00AM: Abstract Number: 1110

Characterization of CD20+ T Cells in Patients with Systemic Sclerosis

9:00AM-11:00AM: Abstract Number: 1117

Characterization of the Esophageal Microbiome in Patients with Systemic Sclerosis (SSc)

9:00AM-11:00AM: Abstract Number: 1121

Characterizing the T Cell Receptor Repertoire in Patients with Systemic Sclerosis

9:00AM-11:00AM: Abstract Number: 1113

Distinct Pathways in Anti-RNP-Associated Pulmonary Hypertension and Anti-RNP-Associated Raynaud’s Phenomenon

9:00AM-11:00AM: Abstract Number: 1112

Downregulated Expression of Interferon Regulatory Factor 8 in Circulating Monocytes Exhibits Pro-Fibrotic Phenotype in Patients with Systemic Sclerosis

9:00AM-11:00AM: Abstract Number: 1107

Expression Quantitative Trait Loci -eQTL- Analysis in Systemic Sclerosis

9:00AM-11:00AM: Abstract Number: 1109

Gene Expressions of TMEM176A and TMEM176B Were Prominent at the Stage of Subclinical Pulmonary Vascular Disease in Systemic Sclerosis

9:00AM-11:00AM: Abstract Number: 1119

Genetic Signatures from RNA Sequencing of Pediatric Localized Scleroderma (LS) Skin

9:00AM-11:00AM: Abstract Number: 1118

Identification of Transcriptional Regulatory Networks in Systemic Sclerosis

9:00AM-11:00AM: Abstract Number: 1115

In Vivo Assessment of Prevention of Lung Fibrosis Using the Pan-PPAR Agonist Lanifibranor in the Tβriiδk-Fib Mouse Model of Systemic Sclerosis

9:00AM-11:00AM: Abstract Number: 1122

Lymphocyte Immunophenotypes at Randomization on the Scleroderma: Cyclophosphamide or Transplantation Trial: Comparison of Treatment Naïve and DMARD Treated Participants with Healthy Controls

9:00AM-11:00AM: Abstract Number: 1104

Mass Cytometry Analysis Detects Dysregulated T Cell Complement Responses in Diffuse Cutaneous Systemic Sclerosis

9:00AM-11:00AM: Abstract Number: 1102

Multi-Organ RNA-Sequencing of Patients with Systemic Sclerosis (SSc) Finds That Intrinsic Subsets Are Conserved across Organ Systems

9:00AM-11:00AM: Abstract Number: 1123

Plasmacytoid Dendritic Cells in Bronchoalveolar Lavage Correlate with Pulmonary Artery Diameter and Infiltrate Perivascular Areas in the Lungs from Patients with Systemic Sclerosis Associated Pulmonary Hypertension

9:00AM-11:00AM: Abstract Number: 1114

Proteomic Aptamer Analysis Reveals a Distinct Profile of Very Early Systemic Sclerosis (SSc) Patients at Risk for Progression Toward Definite SSc

9:00AM-11:00AM: Abstract Number: 1116

Risk of Systemic Sclerosis According to Charge of the HLA-DRβ1 Third Hypervariable Region

9:00AM-11:00AM: Abstract Number: 1106

Signal Transducer and Activator of Transcription 3 (STAT3) Activation in Peripheral Blood Mononuclear Cells of Systemic Sclerosis Patients: Correlation with Disease Specific Manifestations

9:00AM-11:00AM: Abstract Number: 1120

Strong HLA and Novel Non-HLA Associations Identified By Auto-Antibody Subset Analysis of African Americans with Scleroderma from the Genome Research in African American Scleroderma Patients Cohort

9:00AM-11:00AM: Abstract Number: 1103

Systemic Sclerosis Has a Distinct Serum Protein Profile That Correlates with Its Clinical Manifestations

« View all sessions from this meeting

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].